NCT04115189

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA)

A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With Metastatic Renal Cell Carcinoma in Latin America

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 57 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To describe real-world demographic and clinical characteristics, treatment characteristics, and clinical outcomes among patients in Latin America who were treated with first-line sunitinib for metastatic renal cell carcinoma and switched from the 4/2 to 2/1 administration schedule

Detailed description

Understanding characteristics of patients who switched from a 4/2 to a 2/1 sunitinib schedule or initiated the 2/1 schedule in Brazil, and the resulting clinical outcomes in the real-world setting • Describing the occurrence of AEs on the 4/2 and 2/1 schedules

Conditions

• Metastatic Renal Cell Carcinoma ( mRCC)

Interventions

Type	Name	Description
DRUG	Sunitinib	Patients to receive Sunitinib as first line therapy for mRCC

Timeline

• Start date: 2019-12-13
• Primary completion: 2020-12-02
• Completion: 2020-12-02
• First posted: 2019-10-03
• Last updated: 2022-05-10
• Results posted: 2022-05-10

Locations

7 sites across 4 countries: Argentina, Brazil, Colombia, Ecuador